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Catalytic IgG from Patients with Hemophilia A Inactivate
Therapeutic Factor VIII1
Se´bastien Lacroix-Desmazes,2* Bharath Wootla,*† Suryasarathi Dasgupta,* Sandrine Delignat,*
Jagadeesh Bayry,* Joseph Reinbolt,‡ Johan Hoebeke,‡ Evgueni Saenko,§
Michel D. Kazatchkine,* Alain Friboulet,† Olivier Christophe,¶ Valakunja Nagaraja, and
Srini V. Kaveri*
Factor VIII (FVIII) inhibitors are anti-FVIII IgG that arise in up to 50% of the patients with hemophilia A, upon therapeutic
administration of exogenous FVIII. Factor VIII inhibitors neutralize the activity of the administered FVIII by sterically hindering
its interaction with molecules of the coagulation cascade, or by forming immune complexes with FVIII and accelerating its
clearance from the circulation. We have shown previously that a subset of anti-factor VIII IgG hydrolyzes FVIII. FVIII-hydro-
lyzing IgG are detected in over 50% of inhibitor-positive patients with severe hemophilia A, and are not found in inhibitor-
negative patients. Although human proficient catalytic Abs have been described in a number of inflammatory and autoimmune
disorders, their pathological relevance remains elusive. We demonstrate here that the kinetics of FVIII degradation by FVIII-
hydrolyzing IgG are compatible with a pathogenic role for IgG catalysts. We also report that FVIII-hydrolyzing IgG from each
patient exhibit multiple cleavage sites on FVIII and that, while the specificity of cleavage varies from one patient to another,
catalytic IgG preferentially hydrolyze peptide bonds containing basic amino acids. The Journal of Immunology, 2006, 177:
1355–1363.
H emophilia A is an inherited X-linked bleeding disorderthat is characterized by the absence of functional proco-agulant factor VIII (FVIII)3 in the circulation (1). Treat-
ment of hemophilia A with therapeutic administration of FVIII
results in the generation of anti-FVIII Abs of the IgG isotype that
inhibit FVIII activity (FVIII inhibitors) in 50% of the patients
(2). The occurrence of FVIII inhibitors appears as the major com-
plication of hemophilia A treatment. Factor VIII inhibitors neu-
tralize the activity of FVIII by preventing its interaction with other
molecules of the coagulation cascade by steric hindrance (3–8), or
by forming immune complexes that accelerate FVIII clearance
from the circulation (9). In addition to these mechanisms, we have
demonstrated the presence of Abs that hydrolyze FVIII in inhibi-
tor-positive patients with severe hemophilia A (10). FVIII-hydro-
lyzing Abs were found in 50% of inhibitor-positive hemophilic
patients, and were not detected in inhibitor-negative patients (11).
The rates of FVIII hydrolysis were found to correlate with the
inhibitory activities scored in the plasma of the patients (11).
Human proficient catalytic Abs have been described in the con-
text of inflammatory and autoimmune disorders, including asthma,
Hashimoto’s thyroiditis, multiple myeloma, systemic lupus ery-
thematosus, scleroderma, rheumatoid arthritis, multiple sclerosis,
and HIV-related immune thrombocytopenia (12–18). Although
there is evidence supporting a detrimental role for a subset of
platelet-fragmenting Abs in HIV infection (18), the deleterious
role of catalytic Abs in the other disorders remains debated. In this
study, we demonstrate in vitro, in the presence of human serum
albumin (HSA), that the kinetics of FVIII degradation by FVIII-
hydrolyzing IgG are compatible with a pathogenic role for cata-
lytic Abs in inactivation of the therapeutic FVIII administered to
hemophilia A patients. We also report that FVIII-hydrolyzing IgG
from each patient exhibit multiple cleavage sites on FVIII and that,
while the specificities of cleavage vary from one patient to another,
Ab catalysts preferentially hydrolyze peptide bonds containing ba-
sic amino acids. Our findings are critical for the design of generic
neutralizing molecules against anti-FVIII IgG catalysts.
Materials and Methods
Patients
Frozen plasma samples of 24 inhibitor-positive patients with severe hemo-
philia A (plasma FVIII levels 1.0% of normal) were obtained from the
following institutions in accordance with the local ethical regulation: Hoˆ-
pital Cochin (Paris, France), Hoˆpital du Kremlin-Biceˆtre (Biceˆtre, France),
Hoˆpital de Saint-Etienne (Saint-Etienne, France), Gasthuisberg Leuven
(Leuven, Belgium), and the Christian Medical College Hospital (Vellore,
India). Most of the patients had been diagnosed with severe hemophilia A
within the first 2 years of life. The mean age of the patients at the time of
blood sampling was 40.6  18.4 years (mean  SD, ranging from 10 to
70). Patients could be divided in three groups according to the inhibitory
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activity measured in plasma using the Bethesda assay. Mean inhibitory
activities in each group were 2.7  1.5 Bethesda units (BU)/ml (3 low
responder patients, ranging from 1 to 4 BU/ml), 8.5  1.4 BU/ml (4 pa-
tients with moderate inhibitory titers, 6.7–10.0 BU/ml), 65.5 65.0 BU/ml
(17 patients with high inhibitory titers, 12–280), respectively. Plasma from
inhibitor-positive patients with mild hemophilia, and from inhibitor-posi-
tive patients with severe hemophilia undergoing immune tolerance induc-
tion, were not included in our study.
Purification of IgG
IgG was isolated from plasma by 50% ammonium sulfate precipitation
followed by affinity-chromatography on protein G-Sepharose (Amersham
Biosciences). A therapeutic preparation of pooled normal human IgG (i.v.
Ig (IVIg), Sandoglobulin) was used as a source of normal IgG. Size-ex-
clusion chromatography of patients’ IgG and IVIg was performed on a
Superose-12 column (Pharmacia) equilibrated with 50 mM Tris, 8 M urea,
and 0.02% NaN3 (pH 7.7), at a flow rate of 0.25 ml/min to exclude con-
taminating proteases. IgG-containing fractions were then pooled and dia-
lyzed against 50 mM Tris, 100 mM glycine, 0.02% NaN3 (pH 7.7) for 2
days at 4°C. We have previously demonstrated that urea-treated purified
IgG retain the inhibitory activity toward FVIII (11). The purity of IgG
preparations was confirmed 1) by SDS-PAGE and immunoblotting under
nonreducing conditions, 2) by surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry, and 3) by coincubation of the IgG with
a biotinylated suicide inhibitor for serine proteases (phosphonate diester
covalently reactive analog; a gift from Prof. S. Paul, University of Texas,
Houston, TX) followed by detection in Western blot of the biotin-labeled
material. IgG was quantified by ELISA.
Purification of anti-FVIII IgG Abs by affinity chromatography
IgG from patients B1, B2, C1, N1, P1, and Wal reactive to FVIII were
affinity purified on a matrix to which human FVIII had been coupled. Two
different matrices and coupling protocols were used. Twenty-five thousand
units (5 mg) of immunopurified plasma-derived FVIII (LFB) were coupled
to 10 ml of cyanogen bromide-activated Sepharose (Pharmacia). IgG of
patients B2 and C1 were purified as described previously (19). Briefly,
following overnight incubation with the affinity matrix at 4°C and exten-
sive washing with PBS, anti-FVIII IgG were eluted using 0.2 M glycine
(pH 2.8), dialyzed against PBS, 0.01% NaN3 and concentrated with Cen-
triprep (Amicon). Alternatively, 12,000 U (2.4 mg) of human recombinant
FVIII (Hyland) were coupled to 6.7 ml of Affigel-HZ (Bio-Rad) through
glycosylated moieties of FVIII as previously described (20). Following
incubation of IgG from patients B1, N1, and P1 with the FVIII matrix and
extensive washing, anti-FVIII IgG were recovered by sequential acid (50
mM imidazole (pH 4.5), 60% ethylene glycol, 0.5% HSA, 40 mM CaCl2),
and alkaline elutions (50 mM diethylamine (pH 10), 60% ethylene glycol,
40 mM CaCl2), dialyzed, and concentrated.
Biotinylation of Ags
Recombinant human FVIII (Kogenate II; Bayer) was reconstituted in dis-
tilled water to a final concentration of 396 g/ml, desalted on PD-10 col-
umns (Pharmacia) and eluted in 500-l fractions using borate buffer (100
mM borate (pH 7.0), 150 mM NaCl, 5 mM CaCl2). Fractions that con-
tained FVIII as assessed by direct ELISA were pooled. Biotin (440 l at 25
g/ml) was allowed to react with 3 ml of FVIII at 198 g/ml with gentle
agitation in the dark for 2 h at 4°C. Biotinylated FVIII was dialyzed against
borate buffer for 2 h at 4°C, aliquoted, and stored at 20°C until use. The
protocol was essentially identical for the biotinylation of human plasma-
derived albumin (HSA; LFB) and recombinant human factor IX (FIX;
BeneFix; Baxter).
Hydrolysis of biotinylated Ags
Biotinylated FVIII, HSA, and FIX (385 nM) were incubated in 40 l of
catalytic buffer (50 mM Tris-HCl (pH 7.7), 100 mM glycine, 0.025%
Tween 20, and 0.02% NaN3) with the IgG samples (25 g/ml, 167 nM) to
be tested for 12–48 h at 37°C. Samples were mixed with Laemmli buffer
without ME (1:1 v/v), and 20 l of each sample was subjected to 10%
SDS-PAGE. Protein fragments were then transferred onto nitrocellulose
membrane (Schleicher & Schuell). Following overnight blocking in PBS,
1% BSA, 0.1% Tween 20 at 4°C, membranes were incubated with strepta-
vidin-coupled horseradish-peroxidase (Pharmacia) diluted 1/3000 in block-
ing buffer, for 30 min at room temperature. After washing in PBS contain-
ing 0.1% Tween 20, labeled proteins were revealed using the ECL kit
(Amersham Biosciences) and BIOMAX ML films (Kodak). Films were
scanned using a SnapScan 600 (Agfa) scanner.
Determination of FVIII inhibitory activity
FVIII inhibitory activity was measured in purified IgG preparations using
the Bethesda assay (21). Purified IgG and anti-FVIII IgG were incubated
with an equal volume of pooled citrated human plasma (Dade-Behring) for
2 h at 37°C. Residual FVIII activity was measured in a one-stage clotting
assay by determination of the activated partial thromboplastin time using
human plasma depleted of FVIII (Dade-Behring) as substrate, human pla-
cental pathromtin (Behring) as activators and a reference plasma pool
(Dade-Behring). Dilutions were conducted in Owren’s Veronal buffer
(Dade-Behring). Interassay variation ranged between 1 and 2.5%. FVIII
inhibitory activity was expressed as BU per milligram of IgG.
Modified Bethesda assay for FVIII-hydrolyzing Abs
IgG from patient Wal, B1, and from the human monoclonal anti-FVIII B
cell clone B02C11 (a gift from Prof. J. M. Saint-Remy, Center for Molec-
ular and Vascular Biology, Katolische Universitat Leuven, Leuven, Bel-
gium), were incubated at concentrations yielding 70–80% residual FVIII
activity (i.e., 11.2 g/ml, 1 g/ml and 15 ng/ml, respectively) with rFVIII
(3 IU/ml; Kogenate) in Owren Veronal buffer supplemented with 1 mg/ml
HSA, for 2, 4, 8 and 16 h at 37°C. FVIII incubated in Veronal-HSA alone
was used as a control. The residual FVIII activity was determined at each
time point using a conventional one-stage coagulation assay. IVIg, incu-
bated at 11.2 g/ml for up to 16 h as a negative control, did not neutralize
FVIII activity (data not shown).
Sequencing of cleavage fragments
In the case of patients C1, I1, and P1, unlabeled FVIII (300 g, Kogenate
II) was treated with the purified IgG (37 g) in 1.5–3.0 ml of catalytic
buffer for 42–48 h at 37°C. Alternatively, in the case of patient Wal, FVIII
(300 g) was treated with affinity-purified anti-FVIII IgG (74 g) in 1500
l of catalytic buffer for 24 h at 37°C (10). The resultant FVIII cleavage
fragments were run on a 10% SDS-PAGE at 50 mA under nonreducing
conditions and transferred for 2 h at 100 mA on a Hybond-P polyvinyli-
dene difluoride (PVDF) membrane (Amersham Biosciences) in 10 mM
CAPS, 10% ethanol (pH 11.0). After staining with Coomassie blue, visible
bands (molecular mass between 27.3 and 94.1 kDa) were cut and subjected
to N-terminal sequencing for 10 cycles, using an automatic protein micro-
sequencer Prosize 492 cLC (Applied Biosystems). FVIII incubated in
buffer alone did not yield cleavage bands that were detectable upon staining
with Coomassie blue. Amounts of protein sequenced 0.5 pM were con-
sidered significant and above the background level associated with the
experimental conditions. Each visible band in the electrophoretic profiles
yielded 2.4 1.2 different sequences (average SD, ranging from 1 to 7).
Conversely, each individual sequence was detected in 2.8  1.9 electro-
phoretic bands (ranging from 1 to 8). All sequences were identified as
cleavage sites of FVIII.
Hydrolysis of Pro-Phe-Arg-methylcoumarinamide (MCA)
IgG Abs (167 nM) were mixed with proline-phenylalanine-arginine (PFR)
MCA (PFR-MCA; Peptide Inc.) at 0–1.7 mM in 40 l of 50 mM Tris-HCl,
100 mM glycine, 0.025% Tween 20, and 0.02% NaN3 (pH 7.7) in white
96-well U-bottom plates and incubated in the dark for 12–42 h at 37°C.
Hydrolysis of the PFR-MCA substrate was determined by the fluorescence
of the leaving group (aminomethylcoumarin; em 460 nm, ex 370 nm)
using a fluoroscan. Fluorescence values were compared with a standard
curve of free MCA and the corresponding quantities of released MCA were
computed. At each time point, background release of MCA, measured for
each PFR-MCA concentration in wells containing the substrate alone, was
subtracted from the value observed in the presence of the Abs. Data are
expressed as the quantity of released MCA computed at time 0 subtracted
from the quantity of released MCA computed at a given time point, per
amount of time per amount of IgG. The significance of the increase in the
hydrolytic activity of patient IgG as compared with that of IVIg was as-
sessed by an ANOVA and Fischer post hoc tests. The reported p values are
two-sided.
Results
IgG from inhibitor-positive hemophilia A patients hydrolyze
FVIII
We first investigated the capacity of IgG purified from the plasma
of inhibitor-positive patients with hemophilia A to hydrolyze hu-
man recombinant FVIII. FVIII exhibits a characteristic electro-
phoretic pattern, with major protein bands migrating at molecular
masses between 250 and 337 kDa and an additional band at 82 
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2 kDa (Fig. 1). Incubation of FVIII with IgG from inhibitor-pos-
itive patients C1, F1, and P1 resulted in FVIII hydrolysis and in the
generation of up to eight major digestion fragments of molecular
masses ranging from 52.5 to 26.4 kDa (Fig. 1). In contrast, the
migration profile of FVIII remained unchanged when it was incu-
bated in buffer alone (Ctl), or in the presence of normal polyclonal
human IgG (IVIg) (data not shown). IgG from inhibitor-positive
patient R2 did not hydrolyze FVIII either. HSA and recombinant
human FIX, which present single electrophoretic protein bands of
65 and 56 kDa, respectively, were not hydrolyzed when incubated
with IgG of patients C1, F1, P1, and R2, under similar experimen-
tal conditions (Fig. 1).
The hydrolysis of FVIII by IgG was studied in the case of 24
inhibitor-positive patients with severe hemophilia A (11). The mi-
gration profiles of hydrolyzed FVIII were subjected to densitomet-
ric analysis so as to compute the rate of FVIII hydrolysis (Fig. 2,
). IVIg exhibited a marginal hydrolytic activity of 0.04  0.04
pM/min/nM. The latter value was consistently lower than that of
the hydrolytic activity of patients’ IgG. Purified IgG from 13 of the
24 patients with severe hemophilia (patients B1, B2, B3, B4, C1,
C2, F1, H1, I1, N1, P1, V1, and Y1) exhibited a significantly
higher FVIII-hydrolyzing activity than IVIg ( p 0.05). The mean
hydrolytic activity of IgG of these 13 patients was 0.48  0.28
pM/min/nM.
FVIII-hydrolyzing IgG neutralize FVIII procoagulant activity
Using a one-stage coagulation assay, we investigated whether IgG-
mediated hydrolysis of FVIII results in FVIII inactivation. We
diluted the IgG from two inhibitor-positive patients to concentra-
tions at which “classical” FVIII inhibition by steric hindrance mea-
sured in the Bethesda assay, is marginal (75–80% of residual
FVIII activity after 2 h of incubation). We also increased the time
of incubation up to 16 h. In such conditions, classical FVIII in-
hibitors are at equilibrium with FVIII and the residual FVIII ac-
tivity remains constant with time, unless FVIII is hydrolyzed by
anti-FVIII IgG, thus inducing a decrease in the residual FVIII ac-
tivity (Fig. 3A). Incubation of FVIII with a human monoclonal
FVIII inhibitor devoid of FVIII-hydrolyzing activity, BO2C11, re-
sulted in steady levels of residual FVIII activity during 16 h (i.e.,
80.3  5.8%). In contrast, incubation of FVIII with IgG from
patients Wal and B1 resulted in a significant time-dependent de-
crease of residual FVIII activity (Fig. 3B; p  0.01 and p  0.05,
respectively). Thus, at IgG concentrations much inferior to that
found in normal plasma (11.2 and 1 g/ml for IgG from patients
Wal and B1, respectively), half of the FVIII available in the assay
was inactivated after 7 and 16 h, respectively, values inferior or
equal to the normal half-life of therapeutic FVIII in circulation
(22–24). Importantly, the assays were performed in the presence of
1 mg/ml HSA, thus making the experimental conditions close to
physiological ones.
Cleavage site specificity of factor VIII-hydrolyzing IgG
Recombinant human FVIII was incubated with IgG of patients C1,
I1, and P1, and with affinity-purified anti-FVIII IgG of previously
described patient Wal (10). The peptide fragments generated were
resolved by 10% SDS-PAGE and Western blotting before being
subjected to N-terminal sequencing. The latter approach allowed
the identification of scissile bonds located in all domains of FVIII
except those in the C2 domain. The 45 identified protein sequences
all belonged to the FVIII molecule (Table I), indicating the ab-
sence of contamination by adventitious proteins. IgG of patients
Wal, P1, C1, and I1 exhibited 7, 17, 13, and 25 different cleavage
sites each: six of these sites were common to IgG of three patients
(i.e., K36-S37, R336-M337, R740-S741, K974-G975, K992-
V993, K1098-M1099, and R1313-A1314), three sites were com-
mon to two patients (i.e., K408-S409, K661-M662, and R1422-
K1423). The remaining cleavage sites were unique to IgG of
individual patients.
The A1A2, B, and A3C1 domains represent 34.1, 41.8, and
24.1% of the size of the FVIII molecule, respectively, excluding
the C2 domain. The 45 identified cleavage sites were evenly dis-
tributed among the domains (Spearman rank correlation test:  
0.76; r2  0.97; p  0.02). Thus, 39% of the 45 sites were
located in the A1A2 domains, whereas 47% were located in the B
domain and 14% in the A3C1 region, suggesting that catalytic
anti-FVIII IgG have no preferential specificity for either the H
chain, the L chain, or the B domain of FVIII. The amino acid
residues at the 45 scissile bonds differed in charge, size, and hy-
drophobicity. Thus, the site preceding (N-terminal to) the scissile
bond was occupied by K (48.9%), R (35.6%), Y (4.4%), T (2.2%),
M (2.2%), E (2.2%), L (2.2%), or F (2.2%), and the site C-terminal
to the scissile bond by A (2.2%), D (8.9%), E (6.7%), F (4.4%), G
(4.4%), I (2.2%), K (13.3%), M (11.1%), N (4.4%), Q (4.4%), S
(22.2%), T (2.2%), or V (13.3%). Together, cleavages occurred in
84.5% after K or R, indicating that proteolytic IgG preferentially
behave similar to serine proteases.
Using the Swiss-pdb viewer software and the five-domain
model of FVIII that includes amino acids 1–336, 376–716, and
1692–2332 (Table I), we determined that 12 of the 19 cleavage
FIGURE 1. FVIII-hydrolyzing ac-
tivity of IgG purified from plasma of
inhibitor-positive patients with severe
hemophilia A. Biotinylated FVIII,
HSA, and factor IX (385 nM) were
incubated alone (Ctl) or in the pres-
ence of IgG Ab (167 nM) purified
from plasma of patients with severe
hemophilia A for 24 h at 37°C. Sam-
ples were separated by 10% SDS-
PAGE. Results are shown for patients
C1, F1, P1, and R2. Molecular masses
are indicated in the left margin.
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sites available in the model are buried in the molecule (i.e., acces-
sibility 20%), while 7 cleavage sites are exposed at the surface
of FVIII and are readily accessible for interacting with other mol-
ecules. The other IgG cleavage sites on the FVIII molecule, which
are not available in the model and which overlap with the natural
cleavage sites for thrombin, activated factors IX and X (FIXa and
FXa), and activated protein C, i.e., R336-M337, R372-S373,
R740-S741, R1313-A1314, and R1648-E1649 (Table II), can also
be assumed to be highly exposed. Conversely, only few of the
amino acids of FVIII that are exposed at the surface of the mole-
cule, were identified as cleavage sites, thus suggesting that cata-
lytic IgG target specific structures in the FVIII molecule.
IgG from inhibitor-positive patients exhibit hydrolytic activity
toward PRF-MCA
Incubation of patients’ IgG with the peptide PFR-MCA resulted in
hydrolysis of the peptide and release of the fluorescent MCA tag,
thus allowing for the calculation of rates of hydrolysis. Using PFR-
MCA as a substrate enables the study of the kinetics of cleavage at
a single bond (i.e., Arg-MCA), as opposed to the average kinetics
observed when measuring the cleavage of multiple bonds in a large
substrate such as FVIII.
Hydrolysis of PFR-MCA was dose and time dependent (data not
shown). IVIg, used as a negative control, demonstrated a marginal
PFR-MCA-hydrolyzing activity of 0.04  0.04 pM/min/nM (Fig.
2, f). IgG of 13 patients (patients A1, B1, B2, C1, F1, G1, H1, I1,
M1, P1, R1, R2, and Y1) displayed significantly higher hydrolytic
rates toward PFR-MCA than that observed with IVIg ( p  0.05).
IgG of the remaining 11 patients exhibited hydrolysis rates of
PFR-MCA that were either marginal as compared with IVIg or for
which interexperimental differences did not allow to reach signif-
icance. The rate of hydrolysis of PFR-MCA by IgG from patients
B1 and P1 was 19.30  6.17 and 8.22  2.80 pM/min/nM, re-
spectively, which was at least 20-fold higher than the mean hy-
drolysis rate of IgG of the other patients (0.24 0.09 pM/min/nM)
(Fig. 2). Altogether, IgG of 8 of 24 patients (i.e., patients B1, B2,
C1, F1, H1, I1, P1, and Y1) displayed hydrolytic activities signif-
icantly greater than that of IVIg in the case of both FVIII and
PFR-MCA (Fig. 2). Rates of hydrolysis of FVIII and PFR-MCA
for these eight patients were positively correlated (one-tailed
Fisher exact test, p  0.05).
FVIII-specific IgG were further purified by affinity chromatog-
raphy in the case of patients B1, B2, C1, N1, and P1. The yield of
the purifications ranged between 50 and 300 g/10 mg of IgG,
representing relative enrichments of 33- to 200-fold. The specific
FVIII inhibitory activity of unfractionated IgG and of affinity-pu-
rified anti-FVIII IgG were measured by means of the Bethesda
assay. Affinity purification of anti-FVIII IgG resulted in a 65-fold
mean increase in FVIII inhibitory activity (ranging from 11- to
190-fold; Table III), a value which is in the same range as that of
the weight-wise enrichment, demonstrating the specificity for
FVIII of the affinity-purified material.
We then monitored the specific hydrolytic activity of unfrac-
tionated IgG and of affinity-purified anti-FVIII IgG using PFR-
MCA as a substrate. Affinity purification of anti-FVIII IgG re-
sulted in an enrichment in specific hydrolytic activity of PFR
ranging between 2- and 315-fold, with a mean increase of 59-fold
(Table III). These results are in agreement with our previous ob-
servations of an enhancement of hydrolysis of FVIII by affinity-
purified FVIII-specific IgG from patients’ plasma (10, 11). Impor-
tantly, excess of FVIII was able to neutralize IgG-mediated
hydrolysis of PFR-MCA (Fig. 4, shown in the case of patient C1).
The calculated Ki was equal to 0.12  0.01 M.
Together, our data thus indicate that catalytic anti-FVIII IgG is
endowed with a serine protease-like hydrolytic activity and that
PFR-MCA may be a suitable alternative substrate for studying the
kinetic parameters associated with FVIII-specific proteolysis by
patients’ IgG.
Kinetics of proteolysis by catalytic Abs of hemophilic patients
The kinetic parameters of hydrolysis by catalytic anti-FVIII IgG
were calculated in the case of patients B1, B2, B4, C1, F1, I1, and
FIGURE 2. Hydrolysis rates of IgG from inhibitor-positive patients with severe hemophilia A. Biotinylated FVIII (385 nM, ) or the MCA-coupled
PFR peptide (PFR-MCA, 100 M, f) were incubated alone (Ctl) or in the presence of IVIg or of IgG (167 nM) purified from the plasma of 24 patients
for 24 h at 37°C. In the case of FVIII hydrolysis, samples were separated by 10% SDS-PAGE, and the rate of hydrolysis was quantified by scanning of
immunoblots. Spontaneous hydrolysis occurring upon incubation of FVIII in the presence of buffer alone was considered as background and subtracted.
The data represent the means and SDs of femtomoles of FVIII hydrolyzed per minute per nanomole of IgG, for two or three separate experiments. The
mean coefficient of variation was 0.33 (range, 0.01–1.41). In the case of hydrolysis of PFR-MCA, the fluorescence of released MCA was measured.
Spontaneous hydrolysis occurring upon incubation of PFR-MCA in the presence of buffer alone was considered as background and subtracted. The data
represent the means and SDs of three or four separate experiments. The mean coefficient of variation is equal to 0.32 (0.01–1.14). IgG from eight patients
exhibited hydrolysis rates that were significantly greater than that of IVIg both for FVIII and PFR-MCA (, p  0.05, as assessed using the ANOVA post
hoc test).
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P1. In all these cases, incubation of patients’ IgG with increasing
concentrations of PFR-MCA led to the saturation of the hydrolytic
activity toward PFR-MCA (data not shown; r2  0.98). The curves
of the reciprocal of the velocity plotted as a function of the recip-
rocal of the substrate concentration were linear (data not shown),
indicating that the simple Michaelis-Menten kinetics is an appro-
priate model for the reaction. Fitting the experimental data to the
Michaelis-Menten equation allowed the derivation of the apparent
Vmax and average Km of the reactions (Table IV). The computed
kinetic parameters were heterogeneous among patients’ IgG. The
mean apparent Vmax ranged from 6.1 to 609.4 fmol/min. The cal-
culated average Km ranged between 467  125 M and 1400 
1248 M with a mean value of 794.2  300.8 M. The nominal
Kcat values, which represent the sum of the individual constants of
anti-FVIII IgG within each polyclonal preparation, were between
0.03 and 2.61 min1 (Table IV). Computed catalytic efficiencies
were between 37.0 and 3957.7/M/min, respectively.
Discussion
Anti-FVIII Abs in patients’ plasma are a composite mixture of
catalytic and noncatalytic Abs. The FVIII-neutralizing activity of
FVIII inhibitors in vivo thus results from two simultaneous mech-
anisms: steric hindrance of the interaction of FVIII with relevant
molecules of the coagulation cascade, and proteolysis of FVIII by
the subset of Abs with catalytic properties. Although the patho-
logical relevance of the Ab catalysts reported in different autoim-
mune and inflammatory disorders remains elusive, we demonstrate
here that the kinetics of FVIII degradation by FVIII-hydrolyzing
IgG are compatible with a pathological role for catalytic Abs.
The activity of FVIII inhibitors is generally assessed using the
Bethesda assay (21). Although the Bethesda assay requires up to
2 h to reach complete FVIII inactivation, the incubation of FVIII
with purified patients’ IgG requires 24 h before hydrolysis is de-
tected, a 12-fold difference. However, in the Bethesda assay, the
molar ratio of IgG to FVIII is 200 molecules of IgG for 1 mol-
ecule of FVIII (IgG concentration in diluted plasma of a patient
with 1000 BU/ml would be 10 g/ml and FVIII in reference
plasma is 100 ng/ml), whereas it is of 0.5 IgG for one FVIII mol-
ecule in the hydrolysis assay (IgG and FVIII concentrations are 25
and 100 g/ml, respectively), a 400-fold difference. Indeed, the
accuracy of the hydrolysis assay is subject to technical constraints
related to the sensitivity of the detection of digested fragments of
FIGURE 3. FVIII inactivation by FVIII-hydrolyzing
IgG. A, Classical FVIII inhibitors prevent the interac-
tion of FVIII with other molecules of the coagulation
cascade by steric hindrance, and form steady-state in-
teractions with FVIII in in vitro coagulation assays. The
amount of FVIII available for coagulation is thus stable
once equilibrium is reached, i.e., for an incubation pe-
riod above 2 h. In contrast, FVIII-hydrolyzing IgG de-
grade FVIII: the amount of FVIII available for coagu-
lation thus decreases with time. The two mechanisms of
FVIII inactivation may coexist in a single patient. B,
FVIII (3 IU/ml) in Veronal buffer-HSA (1 mg/ml) was
incubated alone or in the presence of IgG from patients
Wal (11.2 g/ml) and B1 (1 g/ml), as well as IgG
from the monoclonal anti-FVIII B cell clone BO2C11
(15 ng/ml) for 2, 4, 8, and 16 h at 37°C. Residual FVIII
activity was measured at each time point using the Be-
thesda assay. The figure depicts the mean residual
FVIII activity (SE mean), relative to the residual ac-
tivity of FVIII incubated in buffer alone, as a function
of time, from two to four independent experiments. The
time-dependent decrease in residual FVIII activity was
significant in the case of IgG from patients Wal (, p 
0.01) and B1 (†, p  0.05), as assessed by a one-way
ANOVA (ns, nonsignificant).
1359The Journal of Immunology
 o
n
 N
ovem
ber 30, 2010
w
w
w
.jimmunol.org
D
ow
nloaded from
 
FVIII in Western blots and the purification of IgG to avoid con-
taminating proteases. If IgG and FVIII could be used at concen-
trations equal to that used in the Bethesda assay, a FVIII hydrolysis
similar to that shown in Fig. 1 would occur in 3.6 min. This hy-
pothesis is strengthened by our earlier observation that affinity-
purified anti-FVIII IgG from patients Wal and Bor completely hy-
drolyzed FVIII in 5 min and 2 h, respectively (10). To formally
demonstrate the pathological relevance of FVIII-hydrolyzing IgG,
we have modified the Bethesda assay so as to minimize the inhib-
itory activity of classical FVIII inhibitors: in the presence of HSA,
we have used IgG at concentrations yielding 75% residual FVIII
activity after 2 h of incubation with FVIII, and we have incubated
IgG and FVIII for up to 16 h. In such conditions, the residual FVIII
activity decreased in a time-dependent manner when FVIII was
incubated with IgG from two patients with FVIII-hydrolyzing Abs,
while it remained constant upon incubation of FVIII in the pres-
ence of a monoclonal noncatalytic FVIII inhibitor.
Our previous attempt to determine the kinetic parameters of
FVIII-hydrolyzing IgG was hampered by the limiting concentra-
tion of FVIII (i.e., 1.7 M), a value far below the calculated av-
erage Km (9.46 5.52 M) (10). In the present report, PFR-MCA,
a synthetic generic substrate for kallikrein and other serine pro-
teases, was used as a surrogate substrate for the precise determi-
nation of the catalytic rate constants for the cleavage reaction (14,
25). Several lines of evidence validate PFR-MCA as a proper al-
ternative substrate for studying the kinetics of proteolytic anti-
FVIII IgG: 1) anti-FVIII IgG are endowed with a serine-protease-
like activity as indicated by the fact that Ab-mediated hydrolysis of
FVIII is inhibited by Pefabloc, but not by EDTA, leupeptin, nor
pepstatin (10); 2) the hydropathicity of PFR was significantly
Table I. Sites of FVIII cleavage by anti-FVIII IgG of hemophilia A patientsa
Sequence of FVIII
Patients
3Db
Accessibility
of Amino
AcidcWal P1 C1 I1
K36-S37 K36-S37 K36-S37  40
R121-E122  30
K127-V128  10
K166-D167  10
R240-S241  10
K251-S252  10
Y323-V324  10
A1–A2 domains R336-M337 R336-M337 R336-M337  40
R372-S373
1–740 K408-S409 K408-S409  30
R418-I419  10
R583-S584  20
R593-F594  40
T646-D647  20
K661-M662 K661-M662  20
F679-M680  20
R698-N699  20
B domain R740-S741 R740-S741 R740-S741
741–1648 R752-Q753
R776-T777
K872-K873
L904-G905
K925-S926
K974-G975 K974-G975 K974-G975
K992-V993 K992-V993 K992-V993
K1040-K1041
K1041-V1042
R1049-M1050
M1076-V1077
K1098-M1099 K1098-M1099 K1098-M1099
K1136-S1137
K1147-N1148
K1149-V1150
R1310-S1311
R1313-A1314 R1313-A1314 R1313-A1314
R1422-K1423 R1422-K1423
K1473-K1474
K1628-Q1629
R1648-E1649
A3-C1 domains K1673-K1674
K1674-E1675
1649–2172 Y1680-D1681
K1693-K1694  50
E1794-D1795  20
K2092-F2093  60
a Human recombinant FVIII (300 g) was incubated with affinity-purified anti-FVIII IgG (74 g) of patient Wal (10) or with unfractionated IgG from the plasma of patients
P1 (37.5 g), CI (37 g), and I1 (37 g). Degradation fragments were separated by 10% SDS-PAGE, transferred onto PVDF membranes and sequenced by Edman degradation.
Cleavage sites in the C2 domain of FVIII, which are not detected in the assay as fragments lower than 23 kDa, were not subjected to N-terminal sequencing. Amino acids that
surround the sites of cleavage are indicated using the single letter code together with the position of the amino acid in the sequence of the processed protein.
b Amino acids which are included in the three-dimensional model of FVIII provided on (http://europium.csc.mrc.ac.uk	).
c Lower limit of the percentage of accessibility of the better of the two amino acids that surround each cleavage site, as determined using SWISS-pdb viewer (http://
us.expasy.org/sprot	). Amino acids with percentages 20 are considered as nonaccessible.
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correlated to that of 336 of the 2330 tripeptides that constitute the
FVIII molecule and to that of 16 of the 45 identified cleavage sites
on FVIII; and 3) excess of FVIII neutralized the hydrolysis of
PFR-MCA by patients’ IgG. PFR-MCA allows the measurement
of the capacity of the Abs to hydrolyze an amide bond indepen-
dently of their affinity for FVIII. PFR-MCA is however inappro-
priate to judge the specific rates of IgG-mediated hydrolysis of
FVIII. Indeed, the rate of FVIII hydrolysis by the Abs is limited by
the affinity of the IgG for FVIII. This may explain the lack of
correlation between the hydrolytic activity of the Abs toward
FVIII and that toward PFR-MCA (Fig. 2).
Based on the derived Kcat values, catalytic IgG cleaved 43.2–
3758.4 molecules of PFR-MCA over the 24-h period of reaction,
indicating that IgG molecules are capable of turnover, a defining
feature of catalysts. The average Km of patients’ IgG for PFR-
MCA (794.2  300.8 M) was 80-fold greater than that scored
previously when using radiolabeled FVIII as a substrate, i.e.,
9.46  5.62 M (10), indicating that the affinity of anti-FVIII IgG
is higher for FVIII than for PFR-MCA. This is reminiscent of
previous observations that the active and Ag-binding sites are spa-
tially separated in the V region of hydrolytic IgG (26). The esti-
mated mean catalytic efficiencies ranged from 68.3 to 2682.8/M/
min. In normal plasma, FVIII is activated by cleavage by thrombin
and FXa, to form a heterotrimer A2/A1/A3-C1-C2 with full pro-
coagulant activity (27). The reported catalytic efficiencies for
FVIII cleavage by thrombin and FXa are 5
 106 and 1
 106/M/s,
respectively (28–31). These values are 103- to 106-fold higher than
the mean catalytic efficiencies that we determined for IgG, thus
potentially questioning the pathophysiological relevance of FVIII-
hydrolyzing IgG. However, in our calculations we assumed that all
anti-FVIII IgG molecules are catalytic, i.e., 17.5 g of anti-FVIII
IgG/mg of IgG (19, 20). Paul et al. (12) have estimated the quantity
of catalytic IgG in the plasma of patients with asthma to be 11
ng/mg of IgG. The concentration of catalytic anti-FVIII IgG we
have considered may thus be up to 1000-fold overestimated, and
the kinetic parameters underestimated to a similar extent. Hence,
the cleavage of FVIII by catalytic IgG might follow similar kinetic
patterns as that seen with natural enzymes that cleave FVIII.
We identified multiple cleavage sites of FVIII by catalytic Abs:
7, 17, 13, and 25 cleavage sites for IgG of patients Wal, P1, C1,
and I1, respectively. Because degradation products that were
smaller than 23 kDa could not be sequenced due to technical con-
straints, scissile bonds located in the C2 domain of FVIII were not
detected and the total number of cleavage sites is likely to be
underestimated. Multiple cleavage of large proteins by catalytic
Abs has already been reported in the case of thyroglobulin and
prothrombin (14, 16). Approximately 50% of cleavages occurred
at Arg-X bonds that are specific for serine proteases including the
conventional coagulation proteases. Thus, some of the identified
scissile bonds are also cleavage sites for thrombin, APC, FIXa,
FXa, and/or intracellular endoproteases (Table II: R336-M337,
R372-S373, R740-S741, R1313-A1314, and R1648-E1649) (32).
However, other sites that are typically cleaved by activated protein
C (R562-G563), FXa (R1721-A1722), FIXa (R1719-N1720), and
thrombin (R1689-S1690) were not detected upon sequencing of
the cleavage fragments, further indicating that IgG was not con-
taminated with conventional proteases. Indeed, the majority of the
characterized scissile bonds (40 of 45) are not targets for coagu-
lation proteases. Close to 85% of cleavages occurred after Lys or
Arg residues, indicating that most FVIII-hydrolyzing IgG behave
as serine proteases and preferentially target peptide bonds that con-
tain basic amino acids.
There was no selectivity of hydrolysis for any particular domain
of FVIII; the identified scissile bonds were evenly distributed
Table III. Catalytic activity of purified IgG and affinity-purified anti-FVIII IgG from the plasma of patients
with severe hemophilia Aa
Patients
Specific Inhibitory Activity
(BU/mg)
Inhibition
Indexb
Specific Hydrolysis Rate of
PFR-MCA (pmol/min/nmol)c
Activity
IndexbIgG Anti-FVIII IgG IgG Anti-FVIII IgG
B1 28 500–800 18-29 25.01 41.14 2
B2 0.3 57 190 0.13 1.57 12
C1 6 64 11 0.14 2.60 18
N1 7 333 48 0.09 28.62 315
P1 8 500–800 63-100 10.20 44.55 4
a IgG were purified from patients’ plasma by ammonium-sulfate precipitation and chromatography on Sepharose-coupled
protein G. FVIII-specific IgG were further purified by affinity chromatography on a human FVIII matrix. Unfractionated IgG and
affinity-purified anti-FVIII IgG were assessed for their specific inhibitory activity towards FVIII in a functional coagulation
assay, and for their specific hydrolytic activity towards PFR-MCA.
b Defined as the ratio of the values obtained for anti-FVIII IgG and for unfractionated IgG.
c Data are representative of two independent experiments.
Table II. Cleavage sites for physiological FVIII-hydrolyzing enzymes (32)
Cleavage Site
on FVIII Serine Protease Involveda Effect
Shared by
Patient’s IgG
R336 Activated protein C, FIXa, FXa Inactivation P1, C1, I1
R372 Thrombin, FXa Activation Wal
R562 Activated protein C Inactivation
R740 Thrombin, FXa Activation P1, C1, I1
R1313 Unidentified endoprotease Intracellular proteolysis Wal, P1, I1
R1648 Unidentified endoprotease Intracellular proteolysis Wal
R1689 Thrombin, FXa Activation
R1719 FIXa Activation
R1721 FXa Activation
a FXa, activated factor X; FIXa, activated factor IX.
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within the FVIII molecule. This in contrast with the previously
reported clustering of the B cell epitopes on the A2, A3, and C2
domains of the FVIII molecule (Fig. 5; reviewed in Ref. 33). Nine
of the 19 cleavage sites included in the three-dimensional model of
FVIII (Table I: aa 323, 336, 583, 593, 661, 679, 698, 1693, and
1794) were located within 15 Å of either one of the known B cell
epitopes for FVIII inhibitors. It remains to be determined whether
multiple cleavages on the FVIII molecule are due to a single poly-
reactive Ab that hydrolyzes several types of peptide bonds, or to a
diverse mixture of catalytic Abs, each with a different binding site
and epitope specificity, but all with a structure required for prote-
olysis. In this respect, multiple cleavage sites for polyclonal IgG of
one patient with asthma (34) and for murine and human monoclo-
nal L chains have previously been reported (16, 35). In our study,
analysis of the accessibility of the identified scissile bonds reveals
that, for each patient, some cleavage sites were located at the sur-
face of the molecule whereas others were not readily accessible.
These results suggest that FVIII hydrolysis by patients’ IgG occurs
in successive steps, i.e., initial cleavages at the level of the exposed
sites followed by an opening of the molecule and additional cleav-
age at the hitherto cryptic sites. Fine temporal analysis of the re-
action should allow the precise sorting of events that characterize
IgG-mediated hydrolysis of FVIII.
The comparison of the decapeptides that overlap the 45 cleavage
sites based on hydropathicity profiles and of the frequency of oc-
currence of amino acids, did not allow us to identify a consensus
linear peptide that could account with certainty for a majority of
the identified scissile bonds. However, it may be that some of the
cleavage activity would only be neutralized by peptides that mimic
conformational rather than linear epitopes, as previously shown for
several of the conventional noncatalytic FVIII inhibitors (36, 37).
Based on the observations that almost 35% of cleavages occurred
after an Arg, that the hydropathicity profile of PFR correlated with
16 of the 45 identified cleavage sites (data not shown) and that
MCA-coupled PFR is an appropriate surrogate substrate for FVIII-
hydrolyzing Abs (10), it may be speculated that a single or a re-
stricted number of PFR-based tripeptides would be of relevance to
block FVIII-specific Ab catalysts. However, their use may require
molecular modifications so as to sharpen their broad specificity for
different conventional serine proteases and their potential adverse
antithrombotic and thrombocytopenic effects (38, 39).
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1362 FVIII-HYDROLYZING IgG IN HEMOPHILIA A
 o
n
 N
ovem
ber 30, 2010
w
w
w
.jimmunol.org
D
ow
nloaded from
 
(De´partement d’He´matologie des Hoˆpitaux de Saint-Etienne, Saint-Eti-
enne, France), Jean-Marie Saint-Remy (Katolische Universitat Leuven,
Leuven, Belgium), Alok Srivastava (Departement of Hematology of the
Christian Medical College Hospital, Vellore, India), and Natalie Stieltjes
(Centre des he´mophiles, Hoˆpital Cochin, Paris, France) for providing us
with plasma samples. Human recombinant FVIII, plasma-derived HSA,
and recombinant FIX were gifts from Bayer Corporation, LFB, and Baxter,
respectively.
Disclosures
The authors have no financial conflict of interest.
References
1. White, G. C., 2nd, and C. B. Shoemaker. 1989. Factor VIII gene and hemophilia
A. Blood 73: 1–12.
2. Ehrenforth, S., W. Kreuz, I. Scharrer, R. Linde, M. Funk, T. Gu¨ngo¨r,
B. Krackhardt, and B. Kornhuber. 1992. Incidence of development of factor VIII
and factor IX inhibitors in haemophiliacs. Lancet 339: 594–598.
3. Saenko, E. L., M. Shima, G. E. Gilbert, and D. Scandella. 1996. Slowed release
of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and
a human antibody is a novel mechanism for FVIII inhibition. J. Biol. Chem. 271:
27424–27431.
4. Arai, M., D. Scandella, and L. W. Hoyer. 1989. Molecular basis of factor VIII
inhibition by human antibodies: antibodies that bind to the factor VIII light chain
prevent the interaction of factor VIII with phospholipid. J. Clin. Invest. 83:
1978–1984.
5. Shima, M., D. Scandella, A. Yoshioka, H. Nakai, I. Tanaka, S. Kamisue,
S. Terada, and H. Fukui. 1993. A factor VIII neutralizing monoclonal antibody
and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit
factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb.
Haemost. 69: 240–246.
6. Zhong, D., E. L. Saenko, M. Shima, M. Felch, and D. Scandella. 1998. Some
human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood
92: 136–142.
7. Foster, P. A., C. A. Fulcher, R. A. Huoghten, S. de Graaf Mahoney, and
T. S. Zimmerman. 1988. Localization of the binding regions of a murine mono-
clonal anti-FVIII antibody and a human anti-factor VIII alloantibody, both of
which inhibit factor VIII procoagulant activity, to amino acid residues threo-
nine351-serine365 of the factor VIII heavy chain. J. Clin. Invest. 82: 123–128.
8. Lubahn, B. C., J. Ware, D. W. Stafford, and H. M. Reisner. 1989. Identification
of a FVIII epitope recognized by a human hemophilic inhibitor. Blood 73:
497–499.
9. Kazatchkine, M. D., Y. Sultan, E. J. Burton-Kee, and J. F. Mowbray. 1980.
Circulating immune complexes containing anti-FVIII antibodies in multitrans-
fused patients with haemophilia A. Clin. Exp. Immunol. 39: 315–320.
10. Lacroix-Desmazes, S., A. Moreau, Sooryanarayana, C. Bonnemain, N. Stieltjes,
A. Pashov, Y. Sultan, J. Hoebeke, M. D. Kazatchkine, and S. V. Kaveri. 1999.
Catalytic activity of antibodies against factor VIII in patients with hemophilia A.
Nat. Med. 5: 1044–1047.
11. Lacroix-Desmazes, S., J. Bayry, N. Misra, M. P. Horn, S. Villard, A. Pashov,
N. Stieltjes, R. d’Oiron, J. M. Saint-Remy, J. Hoebeke, et al. 2002. The preva-
lence of proteolytic antibodies against factor VIII in hemophilia A. N. Engl.
J. Med. 346: 662–667.
12. Paul, S., D. J. Volle, C. M. Beach, D. R. Johnson, M. J. Powell, and R. J. Massey.
1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoanti-
body. Science 244: 1158–1162.
13. Shuster, A. M., G. V. Gololobov, O. A. Kvashuk, A. E. Bogomolova,
I. V. Smirnov, and A. G. Gabibov. 1992. DNA hydrolyzing autoantibodies. Sci-
ence 256: 665–667.
14. Li, L., S. Paul, S. Tyutyulkova, M. D. Kazatchkine, and S. Kaveri. 1995. Cata-
lytic activity of anti-thyroglobulin antibodies. J. Immunol. 154: 3328–3332.
15. Vlassov, A., C. Florentz, M. Helm, V. Naumov, V. Buneva, G. Nevinsky, and
R. Giege. 1998. Characterization and selectivity of catalytic antibodies from hu-
man serum with RNase activity. Nucleic Acids Res. 26: 5243–5250.
16. Thiagarajan, P., R. Dannenbring, K. Matssura, A. Tramontano, G. Gololobov,
and S. Paul. 2000. Monoclonal antibody light chain with prothrombinase activity.
Biochemistry 39: 6459–6465.
17. Ponomarenko, N. A., O. M. Durova, I. I. Vorobiev, A. A. Belogurov, Jr.,
I. N. Kurkova, A. G. Petrenko, G. B. Telegin, S. V. Suchkov, S. L. Kiselev,
M. A. Lagarkova, et al. 2006. Autoantibodies to myelin basic protein catalyze
site-specific degradation of their antigen. Proc. Natl. Acad. Sci. USA 103:
281–286.
18. Nardi, M., S. Tomlinson, M. A. Greco, and S. Karpatkin. 2001. Complement-
independent, peroxide-induced antibody lysis of platelets in HIV-1-related im-
mune thrombocytopenia. Cell 106: 551–561.
19. Moreau, A., S. Lacroix-Desmazes, N. Stieltjes, E. Saenko, S. V. Kaveri, R.
d’Oiron, Y. Sultan, D. Scandella, and M. D. Kazatchkine. 2000. Antibodies to the
FVIII light chain that neutralize FVIII procoagulant activity, are present in the
plasma of non-responder patients with severe hemophilia A and healthy blood
donors. Blood 95: 3435–3441.
20. Gilles, J. G., J. Arnout, J. Vermylen, and J. M. Saint-Remy. 1993. Anti-factor
VIII antibodies of hemophiliac patients are frequently directed towards nonfunc-
tional determinants and do not exhibit isotypic restriction. Blood 82: 2452–2461.
21. Verbruggen, B., I. Novakova, H. Wessels, J. Boezeman, M. van den Berg, and
E. Mauser-Bunschoten. 1995. The Nijmegen modification of the Bethesda assay
for Factor VIII:C inhibitors: improved specificity and reliability. Thromb. Hae-
most. 73: 247–251.
22. Over, J., J. J. Sixma, M. H. Bruine, M. C. Trieschnigg, R. A. Vlooswijk,
N. H. Beeser-Visser, and B. N. Bouma. 1978. Survival of 125iodine-labeled
Factor VIII in normals and patients with classic hemophilia: observations on the
heterogeneity of human factor VIII. J. Clin. Invest. 62: 223–234.
23. Morfini, M., G. Longo, A. Messori, M. Lee, G. White, and P. Mannucci. 1992.
Pharmacokinetic properties of recombinant factor VIII compared with a mono-
clonally purified concentrate (Hemofil M). The Recombinate Study Group.
Thromb. Haemost. 68: 433–435.
24. Fijnvandraat, K., P. H. N. Celie, E. A. M. Turenhout, J. W. ten Cate,
J. A. van Mourik, K. Mertens, M. Peters, and J. Vooberg. 1998. A human al-
loantibody interferes with binding of factor IXa to the factor VIII light chain.
Blood 108: 2347–2352.
25. Gao, Q. S., M. Sun, S. Tyutyulkova, D. Webster, A. Rees, A. Tramontano,
R. J. Massey, and S. Paul. 1994. Molecular cloning of a proteolytic antibody light
chain. J. Biol. Chem. 269: 32389–32393.
26. Sun, M., Q. S. Gao, L. Kirnarskiy, A. Rees, and S. Paul. 1997. Cleavage spec-
ificity of a proteolytic antibody light chain and effects of the heavy chain variable
domain. J. Mol. Biol. 271: 374–385.
27. Eaton, D., H. Rodriguez, and G. A. Vehar. 1986. Proteolytic processing of human
factor VIII: correlation of specific cleavages by thrombin, factor Xa, and acti-
vated protein C with activation and inactivation of factor VIII coagulant activity.
Biochemistry 25: 505–512.
28. Lollar, P., G. J. Knutson, and D. N. Fass. 1985. Activation of porcine factor
VIII:C by thrombin and factor Xa. Biochemistry 24: 8056–8064.
29. Hill-Eubanks, D. C., and P. Lollar. 1990. von Willebrand factor is a cofactor for
thrombin-catalyzed cleavage of the factor VIII light chain. J. Biol. Chem. 265:
17854–17858.
30. Lamphear, B. J., and P. J. Fay. 1992. Proteolytic interactions of factor IXa with
human factor VIII and factor VIIIa. Blood 80: 3120–3126.
31. Regan, L. M., B. J. Lamphear, C. F. Huggins, F. J. Walker, and P. J. Fay. 1994.
Factor IXa protects factor VIIIa from activated protein C. J. Biol. Chem. 269:
9445–9452.
32. Lenting, P. J., J. A. van Mourik, and K. Mertens. 1998. The life cycle of coag-
ulation factor VIII in view of its structure and function. Blood 92: 3983–3996.
33. Lavigne-Lissalde, G., J. F. Schved, C. Granier, and S. Villard. 2005. Anti-factor
VIII antibodies: a 2005 update. Thromb. Haemost. 94: 760–769.
34. Paul, S., M. Sun, R. Mody, S. H. Eklund, C. M. Beach, R. J. Massey, and
F. Hamel. 1991. Cleavage of vasoactive intestinal peptide at multiple sites by
autoantibodies. J. Biol. Chem. 256: 16128–16134.
35. Sun, M., Q. S. Gao, L. Li, and S. Paul. 1994. Proteolytic activity of an antibody
light chain. J. Immunol. 153: 5121–5126.
36. Villard, S., D. Piquer, S. Raut, J. P. Leonetti, J. M. Saint-Remy, and C. Granier.
2002. Low molecular weight peptides restore the procoagulant activity of factor
VIII in the presence of the potent inhibitor antibody ESH8. J. Biol. Chem. 277:
27232–27239.
37. Villard, S., S. Lacroix-Desmazes, T. Kieber-Emmons, D. Piquer, S. Grailly,
A. Benhida, S. V. Kaveri, J. M. Saint-Remy, and C. Granier. 2003. Peptide
decoys selected by phage display block in vitro and in vivo activity of a human
anti-FVIII inhibitor. Blood 102: 949–952.
38. Scott, N. A., G. L. Nunes, S. B. King III, L. A. Harker, and S. R. Hanson. 1994.
Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circu-
lation 90: 1951–1955.
39. Sinha, U., P. Ku, J. Malinowski, B. Y. Zhu, R. M. Scarborough, C. K. Marlowe,
P. W. Wong, P. H. Lin, and S. J. Hollenbach. 2000. Antithrombotic and hemo-
static capacity of factor Xa versus thrombin inhibitors in models of venous and
arteriovenous thrombosis. Eur. J. Pharmacol. 395: 51–59.
1363The Journal of Immunology
 o
n
 N
ovem
ber 30, 2010
w
w
w
.jimmunol.org
D
ow
nloaded from
 
